Several genes that discriminated AML or one of its major subgroups from controls are known diagnostic markers and/or targets for investigational therapies in AML, for example CD11b, CD13, CD14, CD24, CD33 [35,36], CD71 [37], CD81 [38] and CD99 [39], while CD132 has not been investigated concerning its potential role in AML. This evidence concerns the gene TFRC and acute myeloid leukemia.